

Puma Biotechnology

Earnings Call

Commercial Update



May 7, 2020


nerlynx[®]
(neratinib) tablets

Forward-Looking Safe Harbor Statement


This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements, including, but not limited to, any adverse impact on Puma’s business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Puma’s Annual Report on Form 10-K for the year ended December 31, 2019, Puma’s Quarterly Report on Form 10-Q for the period ended March 31, 2020 (once filed), and subsequent reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.



Puma's Pharmacy and Distributor Network




\$48.6 Million Net NERLYNX Revenue in Q1 2020



~30% of Patients in Q1 Started NERLYNX at a Reduced Dose


PERCENT OF PATIENT STARTS AT REDUCED DOSE



- *Reduced Dose defined as fewer than 6 pills per day*

Bottles Sold By Quarter







BOTTLES SOLD BY QUARTER (SP+SD)



• SP = Specialty Pharmacy Network, SD = Specialty Distributor Network; Bottles defined as 180 Pills



Rest of World Partnerships – Timelines

Region	Partner	Expected Regulatory Approval
Australia / SE Asia		<ul style="list-style-type: none"> March 2019 – Approved in Australia December 2019 -- Approved in Singapore
Israel		<ul style="list-style-type: none"> Q2 2020
Canada		<ul style="list-style-type: none"> July 2019 – Approved
Greater China		<ul style="list-style-type: none"> November 2019 – Approved in Hong Kong April 2020 – Approved in China 2H 2020 – Taiwan
Latin America		<ul style="list-style-type: none"> September 2019 – Approved in Argentina Q2/Q3 2020 – Chile 2H 2020 – Ecuador 2021– Brazil, Colombia, Mexico, Peru
Europe Middle East North and West Africa South Africa Turkey		<p>Launch Timelines</p> <ul style="list-style-type: none"> Q4 2019 – Germany-Launched Q4 2019 – United Kingdom-Launched Q4 2019 – Austria-Launched Q1 2020 – Sweden Launched 2020-2022– Rest of Territory
South Korea		<ul style="list-style-type: none"> End of 2020 – NDA Filing

Puma Biotechnology

Earnings Call

Commercial Update



May 7, 2020

nerlynx[®]
(neratinib) tablets